Skip to content

Startup & venture capital news

Neobe raises USD 6.8m for engineered cancer-treatment bacteria

ARC Ventures leads the seed round.

By /

LinkedInX
Neobe: Neobe raises USD 6.8m for engineered cancer-treatment bacteria

Neobe raised USD 6.8 million, also reported as GBP 5 million, in seed funding led by ARC Ventures. Faber, Macmillan Ventures, Proven Connect, Empirical Ventures and 2048 Ventures also participated. The London biotechnology company engineers bacteria intended to break down physical barriers around solid tumours that can prevent treatments from reaching cancer cells. The capital will support development of its lead programme, NEO22, toward a planned regulatory filing in 2028 and strengthen the team. The technology remains preclinical, and no approved treatment or completed human clinical result was announced.

Keep reading

More Funding

All stories